Vinge advises EQT IX in connection with the acquisition of Parexel

December 14, 2021 EU, Competition and Regulatory

Vinge has advised EQT IX on the merger control aspects of EQT IX’s and Goldman Sachs Asset Management’s acquisition of Parexel from Pamplona Capital Management for USD 8.5 billion.

Parexel carries out biopharmaceutical outsourcing services providing a comprehensive suite of Phase I to IV solutions to the world’s biopharmaceutical companies. The acquisition was notified to a number of competition authorities worldwide including to the European Commission. Vinge’s team consisted primarily of Emma Johansson, Johan Wahlbom, Victoria Fredén and Jesper Ekman.


Vinge advises Symrise on its mandatory bid for Swedencare

Symrise AG has made a public mandatory bid for all shares in Swedencare AB (publ).
June 07, 2023

Vinge advises Stride.VC in connection with its investment in Anotherblock

In 2022, Anotherblock launched a blockchain-based marketplace for music rights. The company has through its platform granted fans access to streaming rights from several known artists. The investment round is led by Stride.VC.
May 25, 2023

Vinge advises M42 on its acquisition of Diaverum from Bridgepoint

Vinge is advising M42, an Abu Dhabi-based tech-enabled healthcare company in connection with is acquisition of Diaverum AB.
May 22, 2023